Exploring the role of PMEPA1 in gastric cancer.
Gastric cancer
PMEPA1
Wnt/β-catenin
Journal
Molecular and cellular probes
ISSN: 1096-1194
Titre abrégé: Mol Cell Probes
Pays: England
ID NLM: 8709751
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
17
07
2023
revised:
04
09
2023
accepted:
05
09
2023
medline:
6
12
2023
pubmed:
9
9
2023
entrez:
8
9
2023
Statut:
ppublish
Résumé
Although there are several treatments available for gastric cancer (GC), the prognosis of the disease is still poor due to many factors, such as late diagnosis and tumor heterogeneity. To identify potential therapeutic targets, bioinformatics techniques and clinical sample validation were employed and prostate transmembrane protein androgen induced 1 (PMEPA1) was selected for further study. In the present study, we found that elevated PMEPA1 expression correlates with a worse prognosis and weaker anti-tumor immunity in GC patients. Moreover, our study showed that PMEPA1 not only influences cell proliferation, clone formation, invasion, and migration in vitro, but also plays an important role in GC progression in vivo. Mechanically, PMEPA1 exerts its oncogenic effects through activating the Wnt/β-catenin signaling pathway. Therefore, PMEPA1 is a potential target for treating GC effectively.
Identifiants
pubmed: 37683830
pii: S0890-8508(23)00040-3
doi: 10.1016/j.mcp.2023.101931
pii:
doi:
Substances chimiques
Membrane Proteins
0
PMEPA1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101931Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors state no conflict of interest.